Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England

Journal of Medical Economics

Volumn 18, Issue 11, 2015, Pages 874-885

  Maruszczak, Maciej J ^a   Montgomery, Stephen M ^a   Griffiths, Matthew J S ^a   Bergvall, Niklas ^b   Adlard, Nicholas ^c  

^a Department of Health Economics and Statistics   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

Cost effectiveness; Cost utility; Dimethyl fumarate; Fingolimod; Highly active relapsing remitting multiple sclerosis; Multiple sclerosis

Indexed keywords

FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; COHORT ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; EXPANDED DISABILITY STATUS SCALE; HIDDEN MARKOV MODEL; HUMAN; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; POST HOC ANALYSIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNITED KINGDOM; COST BENEFIT ANALYSIS; DISABILITY; DISEASE COURSE; ECONOMICS; ENGLAND; HEALTH STATUS; MARKOV CHAIN; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DIMETHYL FUMARATE; DISABILITY EVALUATION; DISEASE PROGRESSION; ENGLAND; FINGOLIMOD HYDROCHLORIDE; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MARKOV CHAINS; MODELS, ECONOMETRIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE;

EID: 84945161927     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1056794     Document Type: Article

References (56)

1. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;122:1180-8
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
3. Tremlett H, Zhu F, Petkau J, et al. Natural, innate improvements in multiple sclerosis disability. Mult Scler 2012;18:1412-21
4. Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013;13:128
5. Mackenzie IS, Morant SV, Bloomfield GA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014;85:76-84
6. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
7. McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008;26:847-60
8. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: Current knowledge and future outlook. Eur Neurol 2014;72:132-41
9. electronic Medicines Compendium (eMC). TYSABRI 300 mg concentrate for solution for infusion, 2013. https://www.medicines.org.uk/emc/medicine/18447. Accessed September 8, 2014
10. electronic Medicines Compendium (eMC). Gilenya 0.5mg hard capsules, 2014. http://www.medicines.org.uk/emc/medicine/24443/SPC/. Accessed September 8, 2014
11. Kappos L, Radue E, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
12. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a doubleblind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
14. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
15. Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Neurol 2014;13:247-56
16. Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16
17. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
18. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
19. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-beta in relapsing-remitting multiple sclerosis. CNS drugs 2015;29:71-81
20. National Institute for Health and Care Excellence. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (TA254). London, UK: NICE; 2012
21. electronic Medicines Compendium (eMC). Tecfidera 240 mg gastro-resistant hard capsules, 2014. http://www.medicines.org.uk/emc/medicine/28592. Accessed August 27, 2014
22. electronic Medicines Compendium (eMC). AUBAGIO 14 mg film-coated tablets, 2014. http://www.medicines.org.uk/emc/medicine/28533. Accessed September 22, 2014
23. National Institute for Health and Care Excellence. Teriflunomide for treating relapsing-remitting multiple sclerosis (TA303). London, UK: NICE; 2014
24. National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320). London, UK: NICE; 2014
25. Bergvall N, Sfikas N, Chin P, et al. Efficacy of fingolimod in pre-treated patients with disease activity: Pooled analyses of FREEDOMS and FREEDOMS II (P3.174). Neurology 2014;82(10 Supplement):P3.174
26. European Medicines Agency. Tecfidera: EPAR - Public assessment report. London, UK: EMA; 2013
27. European Medicines Agency. Gilenya-H-C-2202-II-21: EPAR - Assessment Report - Variation. London, UK: EMA; 2014
28. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677
29. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. NICE; 2013 http://www.nice.org.uk/article/pmg9/chapter/Foreword. Accessed October 10, 2014
30. Biogen Idec Ltd. Natalizumab (Tysabri®) for the treatment of adults with highly active relapsing remitting multiple sclerosis. Manufacturer submission of evidence to NICE. London, UK: National Institute for Health and Clinical Excellence: TA127; 2007
31. Biogen Idec Ltd. Dimethyl fumarate for the treatment of adult patients with relapsing remitting multiple sclerosis. Manufacturer submission of evidence. London, UK: National Institute for Health and Care Excellence: TA320; 2013
32. Genzyme. Alemtuzumab for the treatment of relapsing remitting multiple sclerosis in adults. Manufacturer submission of evidence. London, UK: National Institute for Health and Care Excellence: TA312; 2013
33. Genzyme. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis in adults. Manufacturer submission of evidence. London, UK: National Institute for Health and Care Excellence: TA303; 2013
34. Novartis Pharmaceuticals UK Ltd. Fingolimod for the treatment of relapsingremitting multiple sclerosis in adults. Manufacturer submission of evidence. London, UK: National Institute for Health and Clinical Excellence: TA254; 2011
35. School of Health and Related Research (ScHARR). Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis. London, UK: National Institute for Clinical Excellence: TA32; 2001
36. Office for National Statistics. England and Wales, interim life tables, 1980-82 to 2010-2012, 2013. http://www.ons.gov.uk/ons/rel/lifetables/interim-lifetables/2010-2012/rft-ew.xls. Accessed October 22, 2014
37. Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
38. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991
39. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
40. Association of British Neurologists. Guidelines for prescribing in multiple sclerosis. London, UK: Association of British Neurologists; 2009
41. Barendregt JJ. The half-cycle correction: banish rather than explain it. Med Decis Making 2009;29:500-2
42. NHS. National Schedule of Reference Costs 2013-14 for NHS trusts and NHS foundation trusts. London, UK: NHS; 2014
43. NHS. NHS Tariff 2013-14. London, UK: NHS; 2014
44. Curtis L. PSSRU unit costs of health and social care. Personal Social Services Research Unit: Canterbury, UK; 2014
45. Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health 2007;10:386-9
46. Orme M, Kerrigan J, Tyas D. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
47. EuroQoL. Basic infromation on how tp use EQ-5D questionare. Rotterdam, The Netherlands: EuroQoL; 2009
48. Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073
49. European Medicines Agency. Clinical investigation of medicinal products for the treatment of multiple sclerosis. London, UK: EMA; 2012
50. Bergvall N, Lahoz R, Nazareth T, et al. Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: a retrospective analysis using US open and closed data sources. Poster presented at the Joint ECTRIMS/ACTRIMS meeting, September 10-13, 2014, Boston, MA. 2014:P289
51. Cohn S, Bermel RA, Hara-Cleaver C, et al. Comparative Tolerability and Efficacy of Dimethyl Fumarate And Fingolimod in Multiple Sclerosis. Poster presented at the Joint ECTRIMS/ACTRIMS meeting, September 10-13, 2014, Boston, MA, USA. 2014. p 300
52. Cohen JA, von Rosenstiel P, Gottschalk R, et al. Long-term safety of fingolimod: interim evaluation of data from the LONGTERMS trial. Poster presented at the 66th American Academy of Neurology Annual Meeting, April 26-May 3, 2014, Philadelphia, PA. 2014. p 2.210
53. Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of agerelated macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005;46:4016-23
54. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169-89
55. Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
56. Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90